Stocks · Healthcare · Biotechnology
ImmunityBio, Inc. IBRX
$10.29 +10.88% Close, Oct 2, 2026 · NASDAQ · Market cap $10.77B
Strong trend
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $165.8M, up 192.9% from a year earlier, slowing from 351.5% a quarter earlier.
- Operating margin widened to -151.9% from -504.2% a year earlier.
- The diluted share count rose 18.2% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 7%
- Revenue growth, 3-year CAGRTop 1%
- Revenue growth accelerationBottom 3%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 29%
- Gross marginTop 14%
- Operating marginBottom 26%
- Accruals (lower is better)Top 2%
- Interest coverBottom 46%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 47%
- Free-cash-flow yieldTop 44%
- EBITDA / enterprise valueBottom 43%
- Sales / enterprise valueBottom 10%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 6%
- 6-month returnTop 24%
- 1-year return vs S&P 500Top 3%
- Distance from 52-week highTop 26%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 24%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 33%
- Maximum drawdown, 3 yearsBottom 34%
- Beta vs S&P 500 (lower is better)Bottom 20%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 351.5% | 192.9% | ↓ |
| Gross margin | 99.7% | 94.6% | ↓ |
| Operating margin | -504.2% | -151.9% | ↑ |
| FCF margin | -630.1% | -174.0% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 192.9% | 351.5% | ↓ | Top 7% |
| Gross margin | 94.6% | 99.7% | ↓ | Top 14% |
| Operating margin | -151.9% | -504.2% | ↑ | Bottom 26% |
| Net margin | -598.6% | -648.6% | ↑ | — |
| Free-cash-flow margin | -174.0% | -630.1% | ↑ | — |
| Return on invested capital | -45.0% | — | Bottom 29% | |
| Revenue growth, 3-year CAGR | 678.6% | — | Top 1% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -113.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 20.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -53.5 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -3.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -4.68%
- Shareholder yield
- -4.68%
- Share count change, 1 year
- +18.2%
- Share count change, 3-year CAGR
- +33.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -1.7%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $12.00
- Target vs current price
- +16.6%
- Analysts with a rating
- 5
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | -175.0% | -2.8% | +4.8% | +11.2% | — |
| May 7, 2026 | -675.0% | -7.4% | -2.7% | -13.0% | -14.7% |
| Feb 23, 2026 | +25.0% | +13.0% | +12.4% | -2.6% | -8.0% |
| Nov 4, 2025 | +30.0% | -8.0% | -4.4% | -7.5% | +176.5% |
| Aug 5, 2025 | +0.0% | +0.0% | +2.5% | -1.2% | +7.1% |
| May 12, 2025 | -25.0% | +14.0% | +37.2% | +66.2% | +15.0% |
| Mar 3, 2025 | +65.4% | -13.4% | -8.8% | -4.6% | -23.1% |
| Nov 12, 2024 | +22.2% | -9.2% | -8.1% | -14.9% | -37.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.22 | -$0.08 | -175.0% | $51.2M |
| May 7, 2026 | -$0.62 | -$0.08 | -675.0% | $44.2M |
| Feb 23, 2026 | -$0.06 | -$0.08 | +25.0% | $38.3M |
| Nov 4, 2025 | -$0.07 | -$0.10 | +30.0% | $32.1M |
| Aug 5, 2025 | -$0.10 | -$0.10 | +0.0% | $26.4M |
| May 12, 2025 | -$0.15 | -$0.12 | -25.0% | $16.5M |
| Mar 3, 2025 | -$0.09 | -$0.26 | +65.4% | $7.6M |
| Nov 12, 2024 | -$0.14 | -$0.18 | +22.2% | $6.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 69.42× | — | — | Bottom 10% |
| Free-cash-flow yield | -2.68% | — | — | Top 44% |
| Earnings yield | -9.46% | — | — | Bottom 47% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 16
- Days above the 200-day average
- 183
- 50-day average slope (20 days)
- +1.5%
- 200-day average slope (20 days)
- +9.7%
- Distance from 50-day average
- +28.6%
- Distance from 200-day average
- +42.8%
- RSI (14)
- 70.3
- Relative volume
- 2.68×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 65.9%
- Volatility vs own 5-year history
- 13th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.80
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -10.9%
- Maximum drawdown, 3 years
- -79.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 22, 2021 | Oct 19, 2023 | -97.0% | 670 days | Not yet recovered |
| Dec 23, 2020 | Jan 6, 2021 | -27.1% | 8 days | 6 days (Jan 14, 2021) |
| Oct 15, 2020 | Nov 9, 2020 | -26.1% | 17 days | 13 days (Nov 27, 2020) |
| Dec 11, 2020 | Dec 18, 2020 | -16.9% | 5 days | 1 days (Dec 21, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $10.77B
- EPS, diluted (TTM)
- -$0.97
- Revenue (TTM)
- $165.8M
- 52-week range
- $1.95 – $12.43
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $934,000 | $240,000 | $622,000 | $14.7M | $113.3M |
| Gross profit | $934,000 | $240,000 | $622,000 | $14.7M | $112.5M |
| Operating income | -$330.3M | -$351.3M | -$362.3M | -$344.2M | -$256.0M |
| Net income | -$346.8M | -$416.6M | -$583.2M | -$413.6M | -$351.4M |
| EPS (diluted) | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $7.6M | $16.5M | $26.4M | $32.1M | $38.3M | $44.2M | $51.2M |
| Net income | -$85.7M | -$59.2M | -$129.6M | -$92.6M | -$67.3M | -$61.9M | -$632.8M | -$230.4M |
| EPS (diluted) | -$0.12 | -$0.09 | -$0.15 | -$0.10 | -$0.07 | -$0.06 | -$0.62 | -$0.22 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$274.4M | -$337.5M | -$366.8M | -$391.2M | -$304.9M |
| Capital expenditure | -$33.6M | -$78.2M | -$30.6M | -$6.9M | -$3.8M |
| Free cash flow | -$308.0M | -$415.7M | -$397.3M | -$398.1M | -$308.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$4.1M | -$616,000 | $110.4M | $111.4M | $400.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $357.4M
- Total assets
- $628.5M
- Total liabilities
- $1.67B
- Total debt
- $813.1M
- Net debt
- $737.4M
- Shareholders’ equity
- -$1.05B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 125,408,192
- Days to cover
- 15.86
- Change vs previous report
- -0.2%
FINRA short interest, settlement date Sep 15, 2026.